newsfilter
← Latest News
Business Wire·

Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Positive topline results from Phase 2/3 Study ‘302' position VDPHL01 to potentially become the first FDA-approved oral treatment for pattern hair loss in nearly 30 years Upsized IPO and follow-on financing generated